Information on how to access Genotropin® (somatropin, rbe) prescribing information and adverse event reporting can be found at the bottom of the page.
Genotropin is indicated for the treatment of growth disturbance in short children born small for gestational age (SGA), with a birth weight and/or length below - 2 SD, who failed to show catch-up growth by 4 years of age or later.2
Children classified as born small for gestational age may have concurrent diagnoses such as familial short stature, Turner syndrome, or growth hormone deficiency. Approximately 10% of children born small for gestational age do not reach the normal height range. Those whose growth has not caught up by 4 years of age are candidates for treatment with growth hormone.3
Study results: effect of growth hormone (GH) on SGA children treated until final height
Achieving catch-up growth and normalising final height 1
Increase in height following initiation of treatment with growth hormone (GH) (0.033mg/kg/day) 1
Δ GH treated >2 year before puberty
▽ GH treated <2 years before puberty
O Untreated group
Adapted from Dahlgren et al, 2005 1
GH normalised final height in short children born SGA, allowing most patients to reach their target final height.1
Observational study of 77 pre-pubertal short children born SGA (-2SD birth weight or length; mean age 10.7 years) in which patients received 0.033 mg/kg/day GH treatment until final height (1 year after height velocity <1 cm/year). During puberty, 24 children were randomised to 66 µg/kg/day GH. Children were subdivided according to the duration of GH treatment before puberty (>2 years [n=36] and < 2 years [n=41]). Growth response was compared with a comparison group of 34 untreated short pre-pubertal SGA children. Values are means ± standard error (SE). MPH SDS mid-parental height SD score.
Dosage recommendations in SGA Patients |
||
---|---|---|
Indication |
mg/kg body weight dose per day |
mg/m2 body surface area dose per day |
Small for Gestational Age |
0.035 |
1.0 |
Treatment should be discontinued after the first year of treatment if the height velocity SDS is below + 1. Treatment should be discontinued if height velocity is < 2 cm/year and, if confirmation is required, bone age is > 14 years (girls) or > 16 years (boys), corresponding to closure of the epiphyseal growth plates.
Please refer to the Summary of Product Characteristics for full information before prescribing Genotropin
Long-term Treatment of Children with Growth Disturbance due to Born Small for Gestational Age |
||||||
---|---|---|---|---|---|---|
System Organ Class |
Very Common ≥ 1/10 |
Common ≥ 1/100 to <1/10 |
Uncommon ≥ 1/1,000 to <1/100 |
Rare ≥ 1/10,000 to <1/1,000 |
Very Rare <1/10,000 |
Not Known (cannot be estimated from available data) |
Neoplasms Benign, Malignant and Unspecified (including cysts and polyps) |
Leukaemia† |
|||||
Metabolism and Nutrition Disorders |
Type 2 diabetes mellitus |
|||||
Nervous System Disorders |
Paraesthesia* Benign intracranial hypertension |
|||||
Skin and Subcutaneous Tissue Disorders |
Rash** |
Pruritus** |
||||
Musculoskeletal, Connective Tissue and Bone Disorders |
Arthralgia* |
Myalgia* Musculoskeletal stiffness* |
||||
General Disorders and Administration Site Conditions |
Injection site reaction$ |
Oedema peripheral* Face oedema* |
||||
Investigations |
Blood cortisol decreased‡ |
Find out more about NICE’s technology appraisals on the use of Genotropin for Adult Growth Hormone Deficiency
Our dedicated nurse team are on hand to support patients being treated with Genotropin and healthcare professionals who have Genotropin patients
Contact the team
Prescribing Information
Genotropin (somatropin, rbe) 0.2mg Miniquick
Genotropin (somatropin, rbe) 0.4mg MiniQuick
Genotropin (somatropin, rbe) 0.6mg MiniQuick
Genotropin (somatropin, rbe) 0.8mg MiniQuick
Genotropin (somatropin, rbe) 1.2mg MiniQuick
Genotropin (somatropin, rbe) 1.4mg MiniQuick
Genotropin (somatropin, rbe) 1.6mg MiniQuick
Genotropin (somatropin, rbe) 1.8mg MiniQuick
Genotropin (somatropin, rbe) 12mg powder and solvent
Genotropin (somatropin, rbe) 1mg MiniQuick
Genotropin (somatropin, rbe) 2mg MiniQuick
Genotropin (somatropin, rbe) 5.3mg powder and solvent
Watch Dr Helen Turner talk about the early diagnosis of Turner syndrome, the commonest chromosomal disorder in women
Find out more
Watch how a child patient takes Genotropin with the Miniquick device
Find out more
Pfizer offers a range of homecare and patient support services to Genotropin patients
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020
No